Q4 2024 EPS Estimates for GSK plc (NYSE:GSK) Raised by Analyst

GSK plc (NYSE:GSK) – Research analysts at Zacks Research increased their Q4 2024 EPS estimates for shares of GSK in a report issued on Tuesday, June 25th. Zacks Research analyst E. Bagri now expects that the pharmaceutical company will post earnings per share of $0.84 for the quarter, up from their prior estimate of $0.83. The consensus estimate for GSK’s current full-year earnings is $4.11 per share. Zacks Research also issued estimates for GSK’s Q2 2025 earnings at $1.00 EPS.

GSK (NYSE:GSK) last issued its quarterly earnings data on Wednesday, May 1st. The pharmaceutical company reported $1.09 earnings per share for the quarter, topping analysts’ consensus estimates of $0.94 by $0.15. The business had revenue of $9.34 billion during the quarter, compared to analysts’ expectations of $8.98 billion. GSK had a net margin of 14.62% and a return on equity of 51.54%.

Several other equities research analysts also recently issued reports on the stock. Berenberg Bank upgraded shares of GSK to a “strong-buy” rating in a research note on Thursday, June 20th. Citigroup raised GSK to a “strong-buy” rating in a research report on Monday, June 24th. Guggenheim raised GSK from a “neutral” rating to a “buy” rating in a research report on Monday, March 4th. Finally, The Goldman Sachs Group initiated coverage on GSK in a report on Thursday, May 30th. They set a “neutral” rating and a $47.00 target price on the stock. One research analyst has rated the stock with a sell rating, two have given a hold rating, two have issued a buy rating and three have assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $47.00.

GSK Stock Performance

NYSE:GSK opened at $38.50 on Friday. The company has a market cap of $79.79 billion, a P/E ratio of 13.95, a P/E/G ratio of 1.17 and a beta of 0.66. The firm’s 50 day moving average is $42.51 and its two-hundred day moving average is $41.20. GSK has a fifty-two week low of $33.67 and a fifty-two week high of $45.92. The company has a quick ratio of 0.58, a current ratio of 0.87 and a debt-to-equity ratio of 1.15.

GSK Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Thursday, July 11th. Investors of record on Friday, May 17th will be issued a $0.3762 dividend. The ex-dividend date is Thursday, May 16th. This represents a $1.50 annualized dividend and a yield of 3.91%. This is an increase from GSK’s previous quarterly dividend of $0.36. GSK’s dividend payout ratio is presently 53.26%.

Institutional Trading of GSK

Institutional investors have recently made changes to their positions in the stock. Horizon Bancorp Inc. IN lifted its holdings in GSK by 8.9% in the 4th quarter. Horizon Bancorp Inc. IN now owns 3,961 shares of the pharmaceutical company’s stock valued at $147,000 after acquiring an additional 323 shares during the last quarter. Cerity Partners LLC boosted its holdings in GSK by 305.7% during the fourth quarter. Cerity Partners LLC now owns 118,233 shares of the pharmaceutical company’s stock worth $4,383,000 after buying an additional 89,089 shares in the last quarter. JPL Wealth Management LLC bought a new stake in GSK during the fourth quarter worth approximately $1,129,000. Thomasville National Bank grew its position in GSK by 5.3% in the first quarter. Thomasville National Bank now owns 453,795 shares of the pharmaceutical company’s stock worth $19,454,000 after buying an additional 23,022 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its holdings in shares of GSK by 1.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 1,777,695 shares of the pharmaceutical company’s stock valued at $65,883,000 after buying an additional 18,585 shares in the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.

GSK Company Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.